Annual Accounts Payable
$2.12 M
+$701.20 K+49.34%
December 31, 2022
Summary
- As of February 8, 2025, NAVB annual accounts payable is $2.12 million, with the most recent change of +$701.20 thousand (+49.34%) on December 31, 2022.
- During the last 3 years, NAVB annual accounts payable has risen by +$1.01 million (+90.86%).
- NAVB annual accounts payable is now -58.91% below its all-time high of $5.17 million, reached on December 31, 2016.
Performance
NAVB Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$2.07 M
+$62.80 K+3.13%
September 30, 2023
Summary
- As of February 8, 2025, NAVB quarterly accounts payable is $2.07 million, with the most recent change of +$62.80 thousand (+3.13%) on September 30, 2023.
- Over the past year, NAVB quarterly accounts payable has increased by +$62.80 thousand (+3.13%).
- NAVB quarterly accounts payable is now -59.91% below its all-time high of $5.17 million, reached on December 31, 2016.
Performance
NAVB Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
NAVB Accounts Payable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +49.3% | +3.1% |
3 y3 years | +90.9% | +3.1% |
5 y5 years | +148.3% | +3.1% |
NAVB Accounts Payable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +49.3% | -34.7% | +45.7% |
5 y | 5-year | at high | +90.9% | -34.7% | +91.7% |
alltime | all time | -58.9% | +967.1% | -59.9% | +1123.0% |
Navidea Biopharmaceuticals Accounts Payable History
Date | Annual | Quarterly |
---|---|---|
Sep 2023 | - | $2.07 M(+3.1%) |
Jun 2023 | - | $2.01 M(-36.7%) |
Mar 2023 | - | $3.17 M(+49.4%) |
Dec 2022 | $2.12 M(+49.3%) | $2.12 M(+22.1%) |
Sep 2022 | - | $1.74 M(-28.4%) |
Jun 2022 | - | $2.43 M(+55.1%) |
Mar 2022 | - | $1.56 M(+10.1%) |
Dec 2021 | $1.42 M(+22.3%) | $1.42 M(+17.8%) |
Sep 2021 | - | $1.21 M(+11.7%) |
Jun 2021 | - | $1.08 M(-12.5%) |
Mar 2021 | - | $1.23 M(+6.2%) |
Dec 2020 | $1.16 M(+4.5%) | $1.16 M(+4.1%) |
Sep 2020 | - | $1.12 M(-3.9%) |
Jun 2020 | - | $1.16 M(-20.2%) |
Mar 2020 | - | $1.45 M(+30.8%) |
Dec 2019 | $1.11 M(+161.9%) | $1.11 M(+32.6%) |
Sep 2019 | - | $839.00 K(+24.7%) |
Jun 2019 | - | $673.00 K(-21.1%) |
Mar 2019 | - | $852.60 K(+100.8%) |
Dec 2018 | $424.70 K(-50.3%) | $424.70 K(-31.0%) |
Sep 2018 | - | $615.50 K(+35.7%) |
Jun 2018 | - | $453.70 K(-35.2%) |
Mar 2018 | - | $700.20 K(-18.1%) |
Dec 2017 | $855.00 K(-83.4%) | $855.00 K(-30.5%) |
Sep 2017 | - | $1.23 M(-23.3%) |
Jun 2017 | - | $1.60 M(-48.8%) |
Mar 2017 | - | $3.13 M(-39.3%) |
Dec 2016 | $5.17 M(+192.2%) | $5.17 M(+5.5%) |
Sep 2016 | - | $4.89 M(-4.7%) |
Jun 2016 | - | $5.13 M(+77.0%) |
Mar 2016 | - | $2.90 M(+64.2%) |
Dec 2015 | $1.77 M(+19.6%) | $1.77 M(+36.1%) |
Sep 2015 | - | $1.30 M(-4.3%) |
Jun 2015 | - | $1.36 M(-28.8%) |
Mar 2015 | - | $1.91 M(+29.0%) |
Dec 2014 | $1.48 M(-39.0%) | $1.48 M(-37.8%) |
Sep 2014 | - | $2.38 M(+42.0%) |
Jun 2014 | - | $1.67 M(-31.0%) |
Mar 2014 | - | $2.43 M(+0.2%) |
Dec 2013 | $2.42 M(+70.9%) | $2.42 M(+42.1%) |
Sep 2013 | - | $1.70 M(-41.0%) |
Jun 2013 | - | $2.89 M(+54.8%) |
Mar 2013 | - | $1.87 M(+31.6%) |
Dec 2012 | $1.42 M(+107.9%) | $1.42 M(-28.1%) |
Sep 2012 | - | $1.97 M(+101.2%) |
Jun 2012 | - | $979.50 K(+23.7%) |
Mar 2012 | - | $792.00 K(+16.2%) |
Dec 2011 | $681.80 K(-55.2%) | $681.80 K(-34.4%) |
Sep 2011 | - | $1.04 M(-34.1%) |
Jun 2011 | - | $1.58 M(+83.7%) |
Mar 2011 | - | $859.10 K(-43.6%) |
Dec 2010 | $1.52 M(+99.4%) | $1.52 M(-22.4%) |
Sep 2010 | - | $1.96 M(+43.0%) |
Jun 2010 | - | $1.37 M(+25.7%) |
Mar 2010 | - | $1.09 M(+42.9%) |
Dec 2009 | $764.00 K(+5.3%) | $764.00 K(-1.1%) |
Sep 2009 | - | $772.50 K(+44.2%) |
Jun 2009 | - | $535.80 K(-22.6%) |
Mar 2009 | - | $692.30 K(-4.6%) |
Dec 2008 | $725.80 K | $725.80 K(+3.9%) |
Sep 2008 | - | $698.60 K(-5.1%) |
Jun 2008 | - | $736.40 K(-9.7%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2008 | - | $815.10 K(+4.8%) |
Dec 2007 | $778.10 K(+16.4%) | $778.10 K(-0.4%) |
Sep 2007 | - | $781.00 K(-4.8%) |
Jun 2007 | - | $820.80 K(-11.1%) |
Mar 2007 | - | $922.90 K(+38.1%) |
Dec 2006 | $668.30 K(+221.6%) | $668.30 K(+50.7%) |
Sep 2006 | - | $443.60 K(+57.4%) |
Jun 2006 | - | $281.90 K(-33.4%) |
Mar 2006 | - | $423.00 K(+103.6%) |
Dec 2005 | $207.80 K(+4.5%) | $207.80 K(-32.4%) |
Sep 2005 | - | $307.20 K(-26.6%) |
Jun 2005 | - | $418.40 K(+100.8%) |
Mar 2005 | - | $208.40 K(+4.8%) |
Dec 2004 | $198.90 K(-11.6%) | $198.90 K(-13.8%) |
Sep 2004 | - | $230.70 K(-31.4%) |
Jun 2004 | - | $336.30 K(+1.9%) |
Mar 2004 | - | $329.90 K(+46.6%) |
Dec 2003 | $225.00 K(-47.9%) | $225.00 K(-59.2%) |
Sep 2003 | - | $551.80 K(-0.5%) |
Jun 2003 | - | $554.30 K(+25.7%) |
Mar 2003 | - | $441.00 K(+2.1%) |
Dec 2002 | $432.10 K(-11.8%) | $432.10 K(+155.2%) |
Sep 2002 | - | $169.30 K(-48.4%) |
Jun 2002 | - | $328.10 K(+14.6%) |
Mar 2002 | - | $286.20 K(-41.6%) |
Dec 2001 | $489.70 K(-33.1%) | $489.70 K(-8.4%) |
Sep 2001 | - | $534.50 K(-13.2%) |
Jun 2001 | - | $615.70 K(+75.9%) |
Mar 2001 | - | $350.00 K(-52.2%) |
Dec 2000 | $732.00 K(-3.7%) | $732.00 K(+127.0%) |
Sep 2000 | - | $322.40 K(-68.1%) |
Jun 2000 | - | $1.01 M(+124.1%) |
Mar 2000 | - | $451.30 K(-79.5%) |
Dec 1999 | $760.00 K(-73.4%) | - |
Jun 1999 | - | $2.20 M(+10.0%) |
Mar 1999 | - | $2.00 M(-30.0%) |
Dec 1998 | $2.86 M(-25.7%) | $2.86 M(+119.8%) |
Sep 1998 | - | $1.30 M(-31.6%) |
Jun 1998 | - | $1.90 M(-38.7%) |
Mar 1998 | - | $3.10 M(-19.4%) |
Dec 1997 | $3.85 M(+60.3%) | $3.85 M(+92.4%) |
Sep 1997 | - | $2.00 M(+5.3%) |
Jun 1997 | - | $1.90 M(+72.7%) |
Mar 1997 | - | $1.10 M(-54.2%) |
Dec 1996 | $2.40 M(-4.0%) | $2.40 M(+26.3%) |
Sep 1996 | - | $1.90 M(+46.2%) |
Jun 1996 | - | $1.30 M(+8.3%) |
Mar 1996 | - | $1.20 M(-52.0%) |
Dec 1995 | $2.50 M(+56.3%) | $2.50 M(+177.8%) |
Sep 1995 | - | $900.00 K(-10.0%) |
Jun 1995 | - | $1.00 M(-23.1%) |
Mar 1995 | - | $1.30 M(-18.8%) |
Dec 1994 | $1.60 M(+23.1%) | $1.60 M(+14.3%) |
Sep 1994 | - | $1.40 M(+75.0%) |
Jun 1994 | - | $800.00 K(-46.7%) |
Mar 1994 | - | $1.50 M(+15.4%) |
Dec 1993 | $1.30 M(+160.0%) | $1.30 M(0.0%) |
Sep 1993 | - | $1.30 M(+160.0%) |
Jun 1993 | - | $500.00 K(0.0%) |
Mar 1993 | - | $500.00 K(0.0%) |
Dec 1992 | $500.00 K | $500.00 K(+66.7%) |
Sep 1992 | - | $300.00 K |
FAQ
- What is Navidea Biopharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals annual accounts payable year-on-year change?
- What is Navidea Biopharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals quarterly accounts payable year-on-year change?
What is Navidea Biopharmaceuticals annual accounts payable?
The current annual accounts payable of NAVB is $2.12 M
What is the all time high annual accounts payable for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high annual accounts payable is $5.17 M
What is Navidea Biopharmaceuticals annual accounts payable year-on-year change?
Over the past year, NAVB annual accounts payable has changed by +$701.20 K (+49.34%)
What is Navidea Biopharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of NAVB is $2.07 M
What is the all time high quarterly accounts payable for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high quarterly accounts payable is $5.17 M
What is Navidea Biopharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, NAVB quarterly accounts payable has changed by +$62.80 K (+3.13%)